X-Biotix Therapeutics
Waltham
About X-Biotix Therapeutics
X-Biotix Therapeutics specializes in the development of novel small molecule antibiotic scaffolds for multi-drug resistant (MDR) gram-negative pathogens to address the urgent and growing global threat of antibiotic resistance. It applies a multi-target strategy to generate a pipeline of effective antibiotics with inhibitory activity against a wide range of biological targets in essential pathways of gram-negative bacterial cells and which are also predicted to defeat known antibiotic resistance mechanisms. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $7.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2018)
- Website: x-biotixrx.com
- Phone: 1 (781) 209-4413
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/x-biotix-therapeutics-107377 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.